key: cord-0942740-x7ymo85t authors: Augustine, Robin; S, Abhilash; Nayeem, Ajisha; Salam, Shaheen Abdul; Augustine, Priya; Dan, Pan; Monteiro, Pablo; Mraiche, Fatima; Gentile, Carmine; Hansbro, Philip M.; McClements, Lana; Hasan, Anwarul title: Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation date: 2021-11-03 journal: Chem Biol Interact DOI: 10.1016/j.cbi.2021.109738 sha: 5e46da89a9ab11e62b03b0cdc6822d835ff19652 doc_id: 942740 cord_uid: x7ymo85t The rapid spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID‐19), has had a dramatic negative impact on public health and economies worldwide. Recent studies on COVID-19 complications and mortality rates suggest that there is a higher prevalence in cardiovascular diseases (CVD) patients. Past investigations on the associations between pre-existing CVDs and susceptibility to coronavirus infections including SARS‐CoV and the Middle East Respiratory Syndrome coronavirus (MERS-CoV), have demonstrated similar results. However, the underlying mechanisms are poorly understood. This has impeded adequate risk stratification and treatment strategies for CVD patients with SARS-CoV-2 infections. Generally, dysregulation of the expression of angiotensin‐converting enzyme (ACE) and the counter regulator, angiotensin‐converting enzyme 2 (ACE2) is a hallmark of cardiovascular risk and CVD. ACE2 is the main host receptor for SARS-CoV-2. Although further studies are required, dysfunction of ACE2 after virus binding and dysregulation of the renin-angiotensin-aldosterone system (RAAS) signaling may worsen the outcomes of people affected by COVID-19 and with preexisting CVD. Here, we review the current knowledge and outline the gaps related to the relationship between CVD and COVID-19 with a focus on the RAAS. Improved understanding of the mechanisms regulating viral entry and the role RAAS may direct future research with the potential to improve the prevention and management of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for 47 coronavirus disease 19 (COVID-19) and its emergence as a pandemic. SARS-CoV-2 infection 48 has a notably higher prevalence in elderly patients with underlying cardiovascular disease (CVD) 49 and/or diabetes, which represents a huge challenge for healthcare professionals worldwide [1] . 50 Understanding the mechanisms of the association between CVD and increased SARS-CoV-2 51 susceptibility, as well as the development of COVID-19 disease, is therefore critical to better 52 manage patients and prevent complications and death. SARS-CoV-2 is a beta coronavirus and it 53 belongs to the Coronaviridae family that includes SARS-CoV and Middle East Respiratory 54 Syndrome cleavage of spike proteins is followed by fusion of the virus and host cell membranes. This is 120 followed by the development of a funnel-like structure constituted by two heptad repeats in the 121 S2 protein in an antiparallel six-helix bundle, thereby catalyzing fusion followed by the delivery 122 of viral genetic material into the cytoplasm. 123 ACE2 is responsible for metabolizing the key vasoconstrictor, angiotensin II, to angiotensin 124 (1-7). Hence, the ACE2 system acts as a preventive mechanism against MI, hypertension, lung 125 shock, arrhythmias, acute myocardial injury, and sometimes sudden death in CVD patients (Table 160 2 and Figure 2 also confirmed in a cohort of 12 patients with SARS-CoV-2 compared to healthy controls in 356 China [189] . Nevertheless, this finding was not replicated in an American cohort of 30 patients 357 with SARS-CoV-2 compared to 14 healthy controls; which showed no differences in plasma 358 levels of Ang-II or aldosterone, suggesting that Ang-II could be metabolized by a different 359 pathway than ACE2 [206] . Ang-II levels also did not correlate with disease severity. However, 360 the same group also showed low levels of Ang1 and Ang1-7 in the same cohort of 27 SARS-361 CoV-2 positive patients compared to 14 healthy controls; lower levels were also observed in 362 patients admitted to intensive care unit (ICU) compared to non-ICU treated COVID-19 patients. 363 In the future, ACE and ACE2 levels should be determined in conjunction with Ang-II and Ang1-364 7, in order to improve our understanding of the RAAS system regulation by SARS- Strict regulations and the availability of quality patient data in many countries is still a 415 challenge for researchers. This has impeded our understanding of the interactions and 416 mechanisms between SARS-CoV-2 and other comorbidities leading to inadequate management 417 and poor outcomes for high-risk patients. Valuable bioinformatics tools can be utilised to perform 418 predictive in silico modelling using patient data including patients' clinical characteristics, 419 medical history, medications, biochemical and viral data that can enable correlation with clinical 420 outcomes and mortality. Multidisciplinary efforts are required to elucidate the links between 421 COVID-19 disease and other comorbidities such as CVD, and to identify mechanisms and 422 effective treatments that can improved outcomes for patients. 423 424 Figure 4 . In healthy individuals, Angiotensin II is converted into Angiotensin (1-7) via ACE2. 425 However, in COVID19, ACE2 may be dysfunctional due to the binding of SARS-CoV-2, which 426 can affect the conversion of Angiotensin II to Angiotensin (1-7) . This results in the accumulation 427 of Angiotensin II in the infected person and induces proinflammatory, prothrombotic, fibrotic and 428 vasoconstrictive downstream effects. In the presence of CVD, however, the RAAS could be 429 impaired. Consequently, upon infection with SARS-CoV-2, more Angiotensin II could 430 accumulate resulting in serious cardiovascular complications. 431 Many studies report that patients with cardiovascular complications and risk factors are more 433 susceptible to coronavirus infections. Despite the need for further rigorous studies in this field, 434 available data obtained from studies investigating SARS, MERS and COVID-19 patients shows 435 clear epidemiological link. The presence of hypertension or CVDs has also been shown to lead 436 to higher CoV-associated complications. Both SARS and COVID-19 patients have increased 437 incidence of myocardial injury, DIC and coagulopathies. Although the mechanisms implicated, 438 so far, include inflammation and the ACE2 pathway effects, further studies are needed to confirm 439 conflicting results on the involvement of the RAAS system and to establish the effects and 440 pathogenic mechanisms associated with SARS-CoV-2 and cardiovascular complications. middle east respiratory syndrome coronavirus infection MERS, SARS and other coronaviruses as causes of pneumonia WHO | WHO guidelines for the global surveillance of severe acute respiratory syndrome 603 (SARS) Middle East 605 Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis 606 and clinical characteristics Worldometer Coronavirus Live update PERSPECTIVE 692 A 611 Novel Coronavirus Emerging in China A Novel Coronavirus Emerging in China-Key 612 Questions for Impact Assessment An interactive web-based dashboard to track COVID-19 in 614 real time Prevalence of Cardiovascular Comorbidities Severe Acute Respiratory Syndrome, and Middle East 618 Respiratory Syndrome: Pooled Analysis of Published Data Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in 623 Clinical features and 626 outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory 627 distress syndrome Outcomes and Prognostic Factors in 631 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong Acute Respiratory 635 Distress Syndrome in Critically Ill Patients with Severe Acute Respiratory Syndrome Presentation and outcome of Middle East respiratory syndrome in Saudi 640 intensive care unit patients Treatment outcomes for patients with Middle 644 Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus 645 referral center in the Kingdom of Saudi Arabia Clinical characteristics and 648 outcome of ICU admitted MERS corona virus infected patients Rate of intensive care unit admission and 651 outcomes among patients with coronavirus: A systematic review and Meta-analysis, PLoS 652 One COVID-19 654 mortality and ICU admission: The Italian experience Left 657 Ventricular Performance in Patients With Severe Acute Respiratory Syndrome: A 30-Day 658 Echocardiographic Follow-Up Study Cardiovascular 662 complications of severe acute respiratory syndrome Analysis of Deaths During the Severe Acute Respiratory Syndrome 667 (SARS) Epidemic in Singapore Challenges in Determining a SARS Diagnosis MERS transmission and risk factors: a systematic review Clinical determinants 673 of the severity of Middle East respiratory syndrome (MERS): A systematic review and 674 meta-analysis Hospitalization Rates and Characteristics of Patients 682 Hospitalized with Laboratory-Confirmed Coronavirus Disease Cardiovascular manifestations and treatment considerations in COVID-19 The Epidemiological Characteristics of an Outbreak of Coronavirus Diseases (COVID-19) -China Prevalence and predictors of death and severe 692 disease in patients hospitalized due to COVID-19: A comprehensive systematic review and 693 meta-analysis of 77 studies and 38,000 patients Characteristics and Associations with 696 Severity in COVID-19 Patients: A Multicentre Cohort Study from Soluble Angiotensin-Converting Enzyme 2 in Heart Failure. Insights Into the Endogenous 700 Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone System Enzyme Inhibitors and Angiotensin II Blockers With Severity of 705 COVID-19: A Multicenter, Prospective Study Hypertension, medications, and risk of severe COVID-19: A 709 Massachusetts community-based observational study COVID-19): 712 current status and future perspectives Angiotensin-715 converting enzyme 2 is an essential regulator of heart function ACE2 receptor polymorphism: Susceptibility to 718 SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome Molecular simulation studies of the interactions between the 722 human/pangolin/cat/bat ACE2 and the receptor binding domain of the SARS-CoV-2 spike 723 protein A pneumonia outbreak associated with a new coronavirus 728 of probable bat origin Functional and genetic analysis of viral receptor ACE2 733 orthologs reveals a broad potential host range of SARS-CoV-2 Pre-fusion structure of a human 737 coronavirus spike protein, Nat Much More Than Just a Receptor for SARS-COV-2 Structural basis for 742 the recognition of SARS-CoV-2 by full-length human ACE2, Science (80-. ) Structure of MERS-CoV spike receptor-746 binding domain complexed with human receptor DPP4 750 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 751 Proven Protease Inhibitor Counter-754 regulatory 'Renin-Angiotensin' System-based Candidate Drugs to Treat Diseases in SARS-CoV-2-infected patients Regulation of ACE2 in cardiac myocytes and 758 fibroblasts Functional angiotensin-converting 761 enzyme 2 is expressed in human cardiac myofibroblasts Angiotensin converting enzyme-2 confers endothelial protection and attenuates 766 atherosclerosis The role of ACE2 in 769 cardiovascular physiology A crucial role of angiotensin 774 converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury ACE2 activation promotes 778 antithrombotic activity Renin-angiotensin system at the heart of 781 COVID-19 pandemic COVID-19 and cardiovascular 784 disease: from basic mechanisms to clinical perspectives Cardiovascular Complications in Patients with COVID-19: 788 Consequences of Viral Toxicities and Host Immune Response Mechanisms of heart 791 failure with preserved ejection fraction in the presence of diabetes mellitus Multisystem inflammatory syndrome in children in 796 Multisystem inflammatory syndrome in U.S. Children and adolescents The Immunology of Multisystem Inflammatory Syndrome in Children with 810 COVID-19 Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review 813 of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management Multisystem inflammatory syndrome in children: A 818 systematic review Toxic shock-like syndrome and COVID-821 19: A case report of multisystem inflammatory syndrome in children (MIS-C) Clinical Characteristics 826 of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally 827 Associated with SARS-CoV-2 Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) 831 and COVID-19 Treated With Infliximab Multisystem Inflammatory Syndrome in 836 Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection 837 (MIS-C): A Multi-institutional Study from New York City Peripheral 841 immunophenotypes in children with multisystem inflammatory syndrome associated with 842 SARS-CoV-2 infection Cardiovascular disease and COVID-19 COVID-19 Pandemic: 847 Cardiovascular Complications and Future Implications Cardiovascular comorbidities and complications associated 850 with coronavirus disease 2019 The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases 853 (COVID-19) in China Cardiovascular Considerations for 858 Health Care Workers, and Health Systems During the COVID-19 Pandemic Covid-19 -Navigating the uncharted Clinical Characteristics of Covid-19 in Prevalence and impact of 868 cardiovascular metabolic diseases on COVID-19 in China COVID-19): An Updated Systematic Review Clinical Characteristics of Coronavirus 877 Disease 2019 in China COVID-19 and the cardiovascular system 882 Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A 883 systematic review and meta-analysis SARS-CoV-2 Infection 886 and Cardiovascular Disease: COVID-19 Heart The Association of Cardiovascular Diseases and Diabetes 889 Mellitus with COVID-19 (SARS-CoV-2) and Their Possible Mechanisms Caution recommended on COVID-19 treatment with 892 hydroxychloroquine and azithromycin for patients with cardiovascular disease Pathological findings of 896 COVID-19 associated with acute respiratory distress syndrome Coronaviruses and the cardiovascular 899 system: acute and long-term implications Coronavirus fulminant myocarditis saved with 902 glucocorticoid and human immunoglobulin Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 906 (COVID-19) Association of Cardiac Injury with Mortality in Hospitalized 910 Patients with COVID-19 in Wuhan, China Clinical course and risk 914 factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective 915 cohort study Analysis 918 of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan The variety of cardiovascular presentations of 923 COVID-19 Joint HFSA/ACC/AHA Statement Addresses 926 Concerns Re: Using RAAS Antagonists in COVID-19 Chimeric Antigen Receptor T-Cell Therapy for Cancer 931 and Heart: JACC Council Perspectives Effective treatment of severe COVID-19 patients with tocilizumab COVID-19: 938 consider cytokine storm syndromes and immunosuppression COVID-19 Illness and Heart Failure: A Missing Link? Immunity, 943 endothelial injury and complement-induced coagulopathy in COVID-19 Coagulation disorders in coronavirus infected patients: 946 COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past Disseminated Intravascular Coagulation in COVID-19-Insights From the Front Lines | 949 AACC.org Coronavirus blood-clot mystery intensifies Pulmonary Embolism in Patients with COVID-19: 954 Awareness of an Increased Prevalence Pulmonary embolism or pulmonary thrombosis in COVID-19? Is 958 the recommendation to use high-dose heparin for thromboprophylaxis justified? D-dimer levels on admission 961 to predict in-hospital mortality in patients with Covid-19 Endothelial cell infection and 965 endotheliitis in COVID-19 Roles of Coagulation and 968 Fibrinolysis in Angiotensin II-Enhanced Microvascular Thrombosis, Microcirculation The case of complement activation in COVID-19 971 multiorgan impact Loop-Mediated Isothermal Amplification (LAMP): A Rapid, Sensitive, Specific, 975 and Cost-Effective Point-of-Care Test for Coronaviruses in the Context of COVID-19 Rapid antibody-979 based covid-19 mass surveillance: relevance, challenges, and prospects in a pandemic and 980 post-pandemic world Rapid diagnostics of coronavirus disease 2019 in early stages 983 using nanobiosensors: challenges and opportunities Cardiac Surgery and the COVID-19 outbreak: what does it mean? Severe Acute 989 Respiratory Syndrome Coronavirus Infection of Human Ciliated Airway Epithelia: Role 990 of Ciliated Cells in Viral Spread in the Conducting Airways of the Lungs 995 Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques Contribution of monocytes 998 and macrophages to the local tissue inflammation and cytokine storm in COVID-19: 999 Lessons from SARS and MERS, and potential therapeutic interventions Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-1003 2 neuroinvasion from the periphery to the brain Endocrine and 1006 metabolic link to coronavirus infection Infection of cultured intestinal epithelial cells 1010 with severe acute respiratory syndrome coronavirus A novel angiotensin-1014 converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1015 1-9 The protein 1017 expression profile of ACE2 in human tissues TRPC1 expression and 1020 distribution in rat hearts Quantitative mRNA expression profiling 1022 of ACE 2, a novel homologue of angiotensin converting enzyme Organ distribution of 1026 severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS 1027 patients: Implications for pathogenesis virus transmission pathways 1030 SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in 1031 patients with SARS Circulating ACE2 in Cardiovascular and 1034 Kidney Diseases The nucleocapsid protein of the SARS 1037 coronavirus is capable of self-association through a C-terminal 209 amino acid interaction 1038 domain Role of the ACE2/angiotensin 1-7 axis of 1041 the renin-angiotensin system in heart failure Heterozygote loss of ACE2 is sufficient to increase the 1045 susceptibility to heart disease Coronavirus Disease 2019 (COVID-19) and 1048 Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-1049 Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of 1050 Severe Acute Respiratory Syndrome Coronavirus 2 Infec Blood pressure lowering for prevention of cardiovascular disease 1054 and death: A systematic review and meta-analysis Myocardial infarction increases 1058 ACE2 expression in rat and humans Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-1062 converting enzyme 2 expression Angiotensin-converting enzymes and drug discovery in 1065 cardiovascular diseases The ACE2 expression in human heart 1068 indicates new potential mechanism of heart injury among patients infected with SARS-1069 1073 SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI 1074 controversy Specific ACE2 1076 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury 1077 after 2019-nCoV infection A 1081 review on the cleavage priming of the spike protein on coronavirus by angiotensin-1082 converting enzyme-2 and furin Angiotensin-converting 1086 enzyme 2 is a functional receptor for the SARS coronavirus ACE2: From vasopeptidase to SARS virus 1089 receptor Are patients with hypertension and diabetes mellitus at 1092 increased risk for COVID-19 infection? Cell 1096 type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts In vitro and in vivo 1099 identification of clinically approved drugs that modify ACE 2 expression Role of angiotensin-converting enzyme 1103 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan The effects of different angiotensin II type 1 receptor 1107 blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in 1108 pressure overload-induced cardiac remodeling in male mice Olmesartan medoxomil treatment potently improves 1112 cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1113 1-7 mas receptor Angiotensin-converting enzyme 2 in severe acute respiratory 1116 syndrome coronavirus and SARS-CoV-2: A double-edged sword? Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With 1124 Mortality Among Patients With Hypertension Hospitalized With COVID-19 Effects of Angiotensin II Receptor Blockers and ACE Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in 1129 Patients With COVID-19 and Hypertension Angiotensin enzyme inhibitors and angiotensin receptor 1133 blockers as protective factors in COVID-19 mortality: a retrospective cohort study In-hospital use of ACE 1137 inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African 1138 American patients Association of ACE inhibitors and angiotensin type II blockers with 1140 ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study Association of renin-1144 angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with 1145 hypertension: a population-based study Comorbidities in COVID-19: Outcomes in hypertensive 1148 cohort and controversies with renin angiotensin system blockers Renin-angiotensin-aldosterone system inhibitors in patients with covid-19 Upregulation of Angiotensin-Converting Enzyme 2 after Myocardial Infarction by 1155 Blockade of Angiotensin II Receptors Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-1159 converting enzyme isoforms in rats with experimental heart failure Clinical and biochemical indexes from 2019-nCoV infected patients linked 1164 to viral loads and lung injury Outcomes in Patients with COVID-19 Infection 1167 Taking ACEI/ARB Renin-angiotensin system inhibitors improve the clinical outcomes of 1171 COVID-19 patients with hypertension System Inhibitors and Risk of Covid-19 The characteristics and outcomes of 681 severe cases with COVID-19 in China Calcium 1182 channel blockers improve prognosis of patients with coronavirus disease 2019 and 1183 hypertension Outcomes of Hospitalized Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 1190 (COVID-19) OR 1193 BETA-BLOCKERS THERAPY INCREASE THE RISK OF MORTALITY IN COVID 1194 19 PATIENTS? THE RESULTS OF A TERTIARY CENTER IN TURKEY, Hypertens Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angi SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in 1202 patients with COVID-19? To do or not to do: Angiotensin converting enzyme 1205 inhibitors/angiotensin receptor blocker in COVID-19 elderly patients Inpatient Omission of Angiotensin-Converting Enzyme Inhibitors and 1209 Angiotensin Receptor Blockers Is Associated With Morbidity and Mortality in 1210 Coronavirus Disease Association of Renin-Angiotensin System 1213 Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for 1214 COVID-19) Infection in Wuhan, China Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor 1218 ARB) Are Protective Against ICU Admission and Mortality for Patients With 1219 COVID-19 Disease COVID and the Renin-Angiotensin System: Are Hypertension or 1222 Its Treatments Deleterious? Exercise training normalizes ACE and ACE2 in the brain of 1225 rabbits with pacing-induced heart failure Circulating plasma levels of angiotensin II and 1228 aldosterone in patients with coronavirus disease 2019 (COVID-19): A preliminary report Coronavirus Disease 2019 (COVID-19) is Associated with Low Circulating Plasma Levels 1232 of Angiotensin 1 and Angiotensin 1 SARS-CoV-2 entry in host cells-1235 multiple targets for treatment and prevention A Novel Purification Procedure for Active 1240 Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2, Preprints Middle east respiratory syndrome coronavirus 1243 (mers-cov): Infection, immunological response, and vaccine development Role of the Spike Glycoprotein of Human Middle 1246 East Respiratory Syndrome Coronavirus (MERS-CoV) in Virus Entry and Syncytia 1247 Formation Middle East Respiratory Syndrome Coronavirus 1249 Infection Mediated by the Transmembrane Serine Protease TMPRSS2 Mechanisms of coronavirus cell 1252 entry mediated by the viral spike protein The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel 1257 Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by 1258 Neutralizing Antibodies Structure-based discovery of Middle East 1262 respiratory syndrome coronavirus fusion inhibitor Advances in 1265 the relationship between coronavirus infection and cardiovascular diseases Angiotensin-Converting Enzyme 2 1268 and COVID-19: Patients, Comorbidities, and Therapies COVID-19 and the cardiovascular 1274 system: Implications for risk assessment, diagnosis, and treatment options COVID-19 outbreak and decreased hospitalisation 1277 of pregnant women in labour Changes in cardiac arrest patients' temperature management after the ESC Guidance for the Diagnosis and Management of CV 1285 Disease during the COVID-19 Pandemic Heart and lung aquaporins 1289 play a major role in severity of heart failure with preserved ejection fraction in mice and 1290 differs between comorbidities Prevalence of cardiac amyloidosis among elderly 1296 patients with systolic heart failure or conduction disorders High prevalence for obesity in severe COVID-19: Possible 1299 links and perspectives towards patient stratification Angiotensin-1302 Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and 1303 Enzyme Inhibitors) in Coronavirus Disease Proc